Non-secosteroidal VDR ligand (4-{1-ethyl-1-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-propyl}-2-methyl-phenoxy)-hydroxyacetamide 1173 [295] was confirmed to significantly prevent bone loss after daily treatment without inducing hypercalcemia. Here, VDR is linked to hypercalcemia disease.